Multidisciplinary Hospital For Active Treatment Haskovo AD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Multidisciplinary Hospital For Active Treatment Haskovo AD conducts a focused program of clinical research aimed at improving outcomes for patients with cardiovascular diseases. Trials investigate new anticoagulant agents, strategies to prevent recurrent ischemic events after heart attacks or strokes, and innovative approaches to manage bleeding during urgent procedures.
- Anticoagulant therapy for atrial fibrillation
- Prevention of recurrent ischemic stroke after acute non‑cardioembolic events
- Management of bleeding risk in patients requiring urgent surgery
- Lipid‑lowering interventions for severe hypertriglyceridemia
- Evaluation of novel FXIa inhibitors for major adverse cardiovascular events
With 7 active trials and a team of 9 investigators, the site seeks to test new therapies that could reduce the risk of major adverse cardiovascular events and improve safety profiles for patients with conditions such as acute coronary syndrome, atrial fibrillation, and ischemic stroke.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Although the primary emphasis is on cardiovascular health, the hospital also explores inherited metabolic disorders that influence heart disease risk, including studies on severe hypertriglyceridemia as a genetic lipid abnormality.
- Genetic forms of hypertriglyceridemia
- Inherited risk factors for atherosclerotic cardiovascular disease
These investigations aim to evaluate targeted treatments that could modify disease progression in patients with hereditary lipid disorders, supporting the broader mission of reducing cardiovascular complications linked to genetic factors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 56 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1AstraZeneca AB2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multidisciplinary Hospital For Active Treatment Haskovo AD
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections | Micurx Pharmaceuticals Inc. | Phase III | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 56 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Milvexian | 3 | Unknown | 2023-08-04 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.